The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 163:529-531, March 2006
doi: 10.1176/appi.ajp.163.3.529
© 2006 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Lencz, T.
* Articles by Malhotra, A. K.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Lencz, T.
* Articles by Malhotra, A. K.
Related Collections
* Schizophrenia Spectrum Disorders
* Atypical Neuroleptics
* Genetics

Brief Report

DRD2 Promoter Region Variation as a Predictor of Sustained Response to Antipsychotic Medication in First-Episode Schizophrenia Patients

Todd Lencz, Ph.D., Delbert G. Robinson, M.D., Ke Xu,, M.D., Ph.D., Jenny Ekholm, M.S., Serge Sevy, M.D., M.B.A., Handan Gunduz-Bruce, M.D., Margaret G. Woerner, Ph.D., John M. Kane, M.D., David Goldman, M.D., and Anil K. Malhotra, M.D.

OBJECTIVE: All antipsychotics act on the dopamine D2 receptor. The present study extends prior pharmacogenetic investigations of the D2 receptor gene (DRD2) by examining, in first-episode schizophrenia patients, promoter region variation as a predictor of response time to two first-line atypical antipsychotics. METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (A-241G and –141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or olanzapine. Time until sustained response (two consecutive ratings without significant positive symptoms) for rare allele carriers versus wild types was examined by using Kaplan-Meier curves. RESULTS: Relative to wild type homozygotes, G carriers (A–241G) exhibited a significantly faster time until response, whereas –141C Del carriers took a significantly longer time to respond. Diplotype analysis revealed similar results. CONCLUSIONS: These findings suggest that variation in the D2 receptor gene can, in part, explain variation in the timing of clinical response to antipsychotics in patients with first-episode schizophrenia.




This article has been cited by other articles:


Home page
Journal of Pharmacy PracticeHome page
S. G. Leckband, J. R. Bishop, and V. L. Ellingrod
Pharmacogenomics in Psychiatry
Journal of Pharmacy Practice, June 1, 2007; 20(3): 252 - 264.
[Abstract] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org